MXPA00007681A - Composiciones de epotilona. - Google Patents

Composiciones de epotilona.

Info

Publication number
MXPA00007681A
MXPA00007681A MXPA00007681A MXPA00007681A MXPA00007681A MX PA00007681 A MXPA00007681 A MX PA00007681A MX PA00007681 A MXPA00007681 A MX PA00007681A MX PA00007681 A MXPA00007681 A MX PA00007681A MX PA00007681 A MXPA00007681 A MX PA00007681A
Authority
MX
Mexico
Prior art keywords
organic compounds
compositions containing
containing organic
compositions
compounds
Prior art date
Application number
MXPA00007681A
Other languages
English (en)
Spanish (es)
Inventor
Hoogevest Peter Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA00007681(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9802451.6A external-priority patent/GB9802451D0/en
Priority claimed from GBGB9813646.8A external-priority patent/GB9813646D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA00007681A publication Critical patent/MXPA00007681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA00007681A 1998-02-05 1999-02-03 Composiciones de epotilona. MXPA00007681A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802451.6A GB9802451D0 (en) 1998-02-05 1998-02-05 Organic compounds
GBGB9813646.8A GB9813646D0 (en) 1998-06-24 1998-06-24 Organic compounds
PCT/EP1999/000702 WO1999039694A2 (en) 1998-02-05 1999-02-03 Compositions containing organic compounds

Publications (1)

Publication Number Publication Date
MXPA00007681A true MXPA00007681A (es) 2003-07-14

Family

ID=26313062

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA00007681A MXPA00007681A (es) 1998-02-05 1999-02-03 Composiciones de epotilona.

Country Status (36)

Country Link
US (5) US20030203876A1 (enExample)
EP (1) EP1052974B1 (enExample)
JP (2) JP4644364B2 (enExample)
KR (3) KR20080016756A (enExample)
CN (2) CN100396276C (enExample)
AR (1) AR017979A1 (enExample)
AT (1) ATE431733T1 (enExample)
AU (1) AU753519B2 (enExample)
BE (1) BE1012140A3 (enExample)
BR (1) BR9907647B1 (enExample)
CA (1) CA2320182C (enExample)
CL (1) CL2003002786A1 (enExample)
CO (1) CO4920246A1 (enExample)
CY (1) CY1109311T1 (enExample)
CZ (1) CZ303168B6 (enExample)
DE (1) DE69940904D1 (enExample)
DK (1) DK1052974T3 (enExample)
ES (1) ES2324378T3 (enExample)
FR (1) FR2774909B1 (enExample)
HU (1) HUP0101564A3 (enExample)
ID (1) ID26549A (enExample)
IL (2) IL137550A0 (enExample)
IT (1) IT1313549B1 (enExample)
MX (1) MXPA00007681A (enExample)
MY (1) MY125921A (enExample)
NO (2) NO329376B1 (enExample)
NZ (1) NZ506389A (enExample)
PE (1) PE20000272A1 (enExample)
PL (1) PL201329B1 (enExample)
PT (1) PT1052974E (enExample)
RU (1) RU2214246C2 (enExample)
SI (1) SI1052974T1 (enExample)
SK (2) SK287775B6 (enExample)
TR (1) TR200002299T2 (enExample)
TW (1) TW457095B (enExample)
WO (1) WO1999039694A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
JP4183099B2 (ja) 1995-11-17 2008-11-19 ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃおよびｄ、製造法ならびに組成物
WO1998022461A1 (de) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
GB9802451D0 (en) * 1998-02-05 1998-04-01 Ciba Geigy Ag Organic compounds
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
KR100716272B1 (ko) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
JP2004521122A (ja) 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン類似体の非経口製剤
BRPI0206509B8 (pt) 2001-01-25 2021-05-25 R Pharm Us Operating Llc processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
CA2438610A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Treatment of refractory tumors using epothilone derivatives
MXPA03007423A (es) 2001-02-20 2003-11-18 Bristol Myers Squibb Co Derivados de epotilona para tratamiento de tumores refractarios.
CZ305799B6 (cs) 2001-03-14 2016-03-23 Bristol-Myers Squibb Company Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
JP2004519493A (ja) * 2001-03-19 2004-07-02 ノバルティス アクチエンゲゼルシャフト 抗下痢剤およびエポチロンまたはエポチロン誘導体を含む組合せ剤
EP1392664A4 (en) 2001-06-01 2005-01-26 Bristol Myers Squibb Co EPOTHILONE DERIVATIVES
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI341728B (en) 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites
WO2003077903A1 (en) 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
PL372070A1 (en) * 2002-06-10 2005-07-11 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CA2496477C (en) 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004026254A2 (en) 2002-09-23 2004-04-01 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
US7091193B2 (en) 2002-10-09 2006-08-15 Kosan Biosciences Incorporated Therapeutic formulations
WO2004035050A1 (en) * 2002-10-15 2004-04-29 Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College Use of epothilone derivatives for the treatment of hyperparathyroidism
KR100996996B1 (ko) 2002-11-07 2010-11-25 코산 바이오사이언시즈, 인코포레이티드 트랜스-9,10-디히드로에포틸론 ｃ 및 ｄ, 그것의 유사체 및 그것의 제조 방법
MXPA06003835A (es) * 2003-10-09 2006-06-14 Kosan Biosciences Inc Formulaciones terapeuticas.
WO2005034964A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
JPWO2005073223A1 (ja) * 2004-01-29 2007-09-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 マクロライド系化合物の安定化方法
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
CN101506217B (zh) 2006-08-16 2012-09-05 诺瓦提斯公司 埃坡霉素b的晶型及在药物组合物中的用途
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
CN101642453B (zh) * 2009-09-15 2011-03-16 湖南迪诺制药有限公司 一种含有埃坡霉素b的药物制剂
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
ES3024636T3 (en) * 2017-09-27 2025-06-04 Novartis Ag Parenteral formulation comprising siponimod

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IL27947A (en) * 1967-05-09 1972-07-26 Weitzman J Method for the production of thermoplastic resin particles and of mixtures of such particles with additives
JPS56115855A (en) * 1980-02-19 1981-09-11 Toyota Motor Corp Method and apparatus for controlling ignition timing of engine
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法および用途
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
JP4183099B2 (ja) * 1995-11-17 2008-11-19 ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃおよびｄ、製造法ならびに組成物
EP0932399B1 (en) * 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs

Also Published As

Publication number Publication date
NO329376B1 (no) 2010-10-04
AU2722699A (en) 1999-08-23
US20030203876A1 (en) 2003-10-30
CA2320182A1 (en) 1999-08-12
KR20080016756A (ko) 2008-02-21
KR20060002022A (ko) 2006-01-06
PL342629A1 (en) 2001-06-18
ATE431733T1 (de) 2009-06-15
US20060127423A1 (en) 2006-06-15
HK1033809A1 (en) 2001-09-28
ITMI990208A1 (it) 2000-08-04
SK287775B6 (sk) 2011-09-05
DK1052974T3 (da) 2009-08-10
CY1109311T1 (el) 2014-07-02
CL2003002786A1 (es) 2005-02-04
CZ20002834A3 (cs) 2000-11-15
BE1012140A3 (fr) 2000-05-02
CA2320182C (en) 2008-11-25
DE69940904D1 (de) 2009-07-02
JP2002502810A (ja) 2002-01-29
ES2324378T3 (es) 2009-08-05
FR2774909B1 (fr) 2000-07-28
AU753519B2 (en) 2002-10-17
TW457095B (en) 2001-10-01
HUP0101564A2 (hu) 2001-11-28
NO20003930D0 (no) 2000-08-03
EP1052974A2 (en) 2000-11-22
BR9907647A (pt) 2000-11-14
PE20000272A1 (es) 2000-04-17
AR017979A1 (es) 2001-10-24
TR200002299T2 (tr) 2000-11-21
FR2774909A1 (fr) 1999-08-20
KR100669174B1 (ko) 2007-01-17
MY125921A (en) 2006-08-30
RU2214246C2 (ru) 2003-10-20
CZ303168B6 (cs) 2012-05-09
NZ506389A (en) 2003-07-25
SI1052974T1 (sl) 2009-10-31
SK287487B6 (sk) 2010-11-08
US20070060627A1 (en) 2007-03-15
WO1999039694A3 (en) 1999-09-23
NO20003930L (no) 2000-10-04
EP1052974B1 (en) 2009-05-20
PL201329B1 (pl) 2009-03-31
CN100396276C (zh) 2008-06-25
BR9907647B1 (pt) 2014-04-01
ID26549A (id) 2001-01-18
IL137550A0 (en) 2001-07-24
CN1623543A (zh) 2005-06-08
WO1999039694A2 (en) 1999-08-12
HUP0101564A3 (en) 2002-06-28
IL137550A (en) 2010-06-30
US20110124691A1 (en) 2011-05-26
CN1292683A (zh) 2001-04-25
NO20100302L (no) 2000-10-04
US20080221065A1 (en) 2008-09-11
SK11702000A3 (sk) 2001-01-18
JP4644364B2 (ja) 2011-03-02
JP2010090147A (ja) 2010-04-22
KR20010040534A (ko) 2001-05-15
CO4920246A1 (es) 2000-05-29
PT1052974E (pt) 2009-08-07
IT1313549B1 (it) 2002-09-09

Similar Documents

Publication Publication Date Title
MXPA00007681A (es) Composiciones de epotilona.
ZA97343B (en) Improved compositions containing organic compounds.
GB9807779D0 (en) Organic compounds
GB9802251D0 (en) Organic compounds
GB9802725D0 (en) Organic compounds
GB9802249D0 (en) Organic compounds
GB9804265D0 (en) Organic compounds
GB9802355D0 (en) Organic compounds
ZA991789B (en) Organic compounds.
ZA99434B (en) Organic compounds.
GB9815234D0 (en) Organic compositions
GB9828518D0 (en) Organic compositions
GB9804850D0 (en) Organic compounds
GB9809295D0 (en) Organic compounds
GB9803907D0 (en) Organic compounds
GB9803013D0 (en) Organic compounds
GB9802356D0 (en) Organic compounds
GB9804494D0 (en) Organic compounds
GB9802354D0 (en) Organic compounds
GB9802252D0 (en) Organic compounds
GB9804577D0 (en) Organic compounds
GB9804849D0 (en) Organic compounds
GB9802450D0 (en) Organic compounds
GB9802250D0 (en) Organic compounds
GB9805104D0 (en) Organic compounds

Legal Events

Date Code Title Description
FG Grant or registration